BORA PHARMACEUTICALS LTD (6472) — Cash Flow-to-Debt Ratio
BORA PHARMACEUTICALS LTD (6472) has a Cash Flow-to-Debt Ratio of 0.02x as of March 2026, meaning its operating cash flow of NT$568.46 Million could theoretically repay 0% of its total liabilities (NT$28.70 Billion) in one year. Check BORA PHARMACEUTICALS LTD (6472) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BORA PHARMACEUTICALS LTD Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for BORA PHARMACEUTICALS LTD across 7 annual periods. Also explore 6472 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year debt coverage analysis for BORA PHARMACEUTICALS LTD. For market capitalisation and broader financial context, see 6472 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | NT$4.24 Billion | NT$27.24 Billion | ▲ +385.6% |
| 2024 | 0.03x | NT$980.81 Million | NT$30.59 Billion | ▼ -90.8% |
| 2023 | 0.35x | NT$4.61 Billion | NT$13.29 Billion | ▲ +204.4% |
| 2022 | 0.11x | NT$2.01 Billion | NT$17.62 Billion | ▼ -61.1% |
| 2021 | 0.29x | NT$1.24 Billion | NT$4.22 Billion | ▲ +648.2% |
| 2020 | 0.04x | NT$177.79 Million | NT$4.54 Billion | ▼ -70.8% |
| 2019 | 0.13x | NT$231.77 Million | NT$1.73 Billion | — |